iBio IBIO Stock
iBio Price Chart
iBio IBIO Financial and Trading Overview
iBio stock price | 3.91 USD |
Previous Close | 0.69 USD |
Open | 0.7 USD |
Bid | 0 USD x 1200 |
Ask | 0.78 USD x 1800 |
Day's Range | 0.68 - 0.74 USD |
52 Week Range | 0.36 - 16.5 USD |
Volume | 1.15M USD |
Avg. Volume | 678.32K USD |
Market Cap | 11.8M USD |
Beta (5Y Monthly) | -3.219718 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 1.3 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1 USD |
IBIO Valuation Measures
Enterprise Value | 24.49M USD |
Trailing P/E | N/A |
Forward P/E | -0.29279166 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 23.65522 |
Price/Book (mrq) | 0.63939947 |
Enterprise Value/Revenue | 49.078 |
Enterprise Value/EBITDA | -0.482 |
Trading Information
iBio Stock Price History
Beta (5Y Monthly) | -3.219718 |
52-Week Change | -90.96% |
S&P500 52-Week Change | 20.43% |
52 Week High | 16.5 USD |
52 Week Low | 0.36 USD |
50-Day Moving Average | 0.98 USD |
200-Day Moving Average | 2.05 USD |
IBIO Share Statistics
Avg. Volume (3 month) | 678.32K USD |
Avg. Daily Volume (10-Days) | 1.21M USD |
Shares Outstanding | 16.8M |
Float | 16.65M |
Short Ratio | 4.76 |
% Held by Insiders | 3.05% |
% Held by Institutions | 18.65% |
Shares Short | 888.48K |
Short % of Float | 5.29% |
Short % of Shares Outstanding | 5.29% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -10873.54% |
Gross Margin | 56.71% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -42.45% |
Return on Equity (ttm) | -114.82% |
Income Statement
Revenue (ttm) | 499K USD |
Revenue Per Share (ttm) | 0.05 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 2.17M USD |
EBITDA | -50825000 USD |
Net Income Avi to Common (ttm) | -55557000 USD |
Diluted EPS (ttm) | -144.7 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 6.56M USD |
Total Cash Per Share (mrq) | 0.39 USD |
Total Debt (mrq) | 18.43M USD |
Total Debt/Equity (mrq) | 105.98 USD |
Current Ratio (mrq) | 1.216 |
Book Value Per Share (mrq) | 1.099 |
Cash Flow Statement
Operating Cash Flow (ttm) | -36969000 USD |
Levered Free Cash Flow (ttm) | -43562624 USD |
Profile of iBio
Country | United States |
State | TX |
City | Bryan |
Address | 8800 HSC Parkway |
ZIP | 77807-1107 |
Phone | 979 446 0027 |
Website | https://www.ibioinc.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 105 |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202 , which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
Q&A For iBio Stock
What is a current IBIO stock price?
iBio IBIO stock price today per share is 3.91 USD.
How to purchase iBio stock?
You can buy IBIO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for iBio?
The stock symbol or ticker of iBio is IBIO.
Which industry does the iBio company belong to?
The iBio industry is Biotechnology.
How many shares does iBio have in circulation?
The max supply of iBio shares is 9.87M.
What is iBio Price to Earnings Ratio (PE Ratio)?
iBio PE Ratio is 3.00769260 now.
What was iBio earnings per share over the trailing 12 months (TTM)?
iBio EPS is 1.3 USD over the trailing 12 months.
Which sector does the iBio company belong to?
The iBio sector is Healthcare.
iBio IBIO included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NYSE AMEX COMPOSITE INDEX XAX | 5131.8 USD — |
+0.5
|
— — | 5046.58 USD — | 5131.84 USD — | — - | — — |
- {{ link.label }} {{link}}